A large, open-label study of proglumetacin in the treatment of patients with cervical and low-back pain
(1995) Current Therapeutic Research : clinical and experimental — Vol. 56, n° 12, p. 1237-1246 (1995)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 463.95 KB
Details
- Authors
- Abstract
- In an uncontrolled, open-label, multicenter study, 711 outpatients with either cervical pain (n = 200) or low-back pain (n = 511) received 450 mg/d of proglumetacin, a pro-drug of indomethacin. After 7 days of treatment, a highly significant reduction in pain and an improvement in function were observed in both groups of patients (P < 0.001). The incidence of side effects (10.5%), mainly gastrointestinal (8.7%), was low, especially compared with that associated with indomethacin. Approximately half (47%) of the patients who developed side effects were able to continue proglumetacin treatment; only 2% of all patients in the study had to discontinue the treatment. Thus proglumetacin appears to be a good alternative to indomethacin as a drug of choice for treating patients with cervical and low-back pain.
- Affiliations
Citations
Ginsberg, F., & Lefebvre, D. (1995). A large, open-label study of proglumetacin in the treatment of patients with cervical and low-back pain. Current Therapeutic Research : clinical and experimental, 56(12), 1237-1246. https://doi.org/10.1016/0011-393X(95)85067-8 (Original work published 1995)